Camrelizumab Combined With Anlotinib Hydrochloride and Paclitaxel Albumin-based First-line Treatment of Advanced Mucosal Melanoma:a Single-arm, Multicenter, Open Label Exploratory Study
Latest Information Update: 21 Aug 2023
At a glance
- Drugs Camrelizumab (Primary) ; Catequentinib (Primary) ; Paclitaxel (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 03 Aug 2021 New trial record
- 27 Jul 2021 Planned End Date changed from 3 Aug 2023 to 14 Aug 2023.